

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 58114

Title: Clinical Implications, Diagnosis, and Management of Diabetes in Patients with Chronic Liver Diseases

Reviewer's code: 00049727

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: United States

Manuscript submission date: 2020-07-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-07-08 03:41

Reviewer performed review: 2020-07-08 04:39

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

This is a comprehensive review about the mechanism and management of DM in patients with chronic liver disease (CLD), including HCV, NAFLD/NASH, and cirrhosis. This review is well written and of great value because clinicians are sometimes worried about glucose control for CLD patients. Major comments 1. HCV and insulin resistance: The authors should cite the following manuscript and mention the role of HCV core protein for hepatic insulin resistance: Shintani et al., *Gastroenterology*. 2004 Mar;126(3):840-8. doi:10.1053/j.gastro. 2003. 11.056. PMID: 14988838. 2. Section 8 3: The authors titled "Acarbose". There are some alpha-glucosidase inhibitors other than acarbose. The authors should seek the manuscripts more broadly. 3. Section 8 3: The authors should cite the following manuscript and mention the efficiency and safety of alpha-glucosidase inhibitor for treating NASH: Komatsu et al., *Hepatol Res*. 2018 Dec;48(13):1092-1098. doi: 10.1111/ hepr. 13223. Epub 2018 Jul 27. PMID: 29935004 4. The authors should discuss the association between sulfonylurea intake and HCC in CLD patients.

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 58114

Title: Clinical Implications, Diagnosis, and Management of Diabetes in Patients with Chronic Liver Diseases

Reviewer's code: 02539650

Position: Peer Reviewer

Academic degree: DPhil

Professional title: Assistant Professor, Doctor

Reviewer's Country/Territory: Hungary

Author's Country/Territory: United States

Manuscript submission date: 2020-07-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-07-08 09:13

Reviewer performed review: 2020-07-13 15:42

Review time: 5 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

In this manuscript titled „Clinical Implications, Diagnosis, and Management of Diabetes in Patients with Chronic Liver Diseases” authored by Waihong Chung, Kittichai Promrat and Jack Wands a complex task is reviewed. General opinion: The MS is generally well written, clear and reviews this complex, difficult topic using 226 references. Structure is organized in a logical manner, the task is of high interest to the clinicians due to that both patient populations (T2DM and NAFLD) are huge World wide and the overlap is substantial. Therefore the general opinion is supportive. Nevertheless there are a few points where the MS could be potentially improved as follows: a-) Page 1 – point 2. (“Diabetes and chronic liver disease”), 1st paragraph: Authors do refer to the ADA guideline as one that “now make specific recommendations regarding screening patient s with prediabetes and T2DM for NAFLD”. While this statement is true there are other major recognized organizations who even jointly published guidelines to help treatment such as the “Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease” by the EASL-EASD-EASO1 and “The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases”². These guidelines should also be incorporated and cited appropriately. b-) Page 1 – point 2., 3rd paragraph: Authors characterized the relationship between DM and HCV as “particularly noteworthy”. Accordingly a number of experimental and clinical observations are lined up to support this relationship. However one major path that may contribute to the risk of (type 2) DM development in patients with chronic HCV infection is still missing: The increased serum DPP-4 activity^{3,4} and CD26 expression in human hepatoma cell line transfected by HCV non-structural (NS) genome region cDNA⁵ may potentially also have a DM inducing effect via the increased degradation of the incretin hormones. c-)

Page 2 – point 3 (“Diabetes and End-Stage Liver Diseases) - 2nd and 3rd paragraph Authors outline that the incidence of HCC and HCC-specific mortality are nearly double in patients with pre-existing DM and give a good overview of the topic including even the treatment modalities such as TACE. However, the genetic susceptibility is not discussed. It is somehow missing from the whole review, despite it would be particularly relevant in this chapter. Hassan et al reported a higher risk of HCC for subjects with a homozygous GG genotype of the rs738409 variant of PNPLA3 (aOR: 3.21), however among individuals with diabetes mellitus the adjusted OR nearly reached a 20-fold increased (19.1) indicating a significant interplay between PNPLA3 genotype and DM on HCC as an outcome.⁶ This aspect should also be included here. d-) Page 5. point 6.3 (“Hemoglobin A1c”) Correct writing of Hemoglobin A1c is as follows: Hemoglobin A1c In addition based on this paragraph it might be the impression of the reader that the HbA1c is not a good marker in any chronic liver disease. However due to that the NAFLD/MAFLD is the most common CLD in the more advanced countries where – in vast majority of the cases – HbA1c is not only a good, but an essential marker of mean glycemic control back to 2-3 months and monitoring, but also is appropriate for diagnosis in diabetes care I would suggest to temper down the tone of this paragraph. The NGSP lists the conditions that interfere with HbA1c measurement (<http://www.ngsp.org/factors.asp>). Perhaps the authors are correct on that the more advanced CLD cases, in particular when co-occurring with other diseases/complications such as nutritional and vitamin deficiencies (folate, B12), portal hypertension with hypersplenism most likely should be mentioned, however I would suggest to temper down the tone of this paragraph (in particular, where references 89 and 90 cited, e.g.: “The accuracy and validity of A1c in patients with liver disease is suboptimal”), etc. e-) Page 9. point 8.5. (“Dipeptidyl peptidase-4 inhibitors”) A few studies with DPP-4 inhibitors or even the drug names are missing. I.e.: the authors left out Vildagliptin from

the list of DPP-4 inhibitors. The studies reporting positive effect of DPP-4 inhibitors of live endpoints, but currently missing from this review are: 1. Alam et al published that Sitagliptin 100 mg once daily for 1 year ameliorates NAS by improving steatosis and ballooning, irrespective of diabetes.⁷ 2. Kosi-Trebotic et al reported that 6 months of DPP-4-therapy led to a significant overall decrease in HCL and body weight such as a reduction of myocardial fat content only in women.⁸ f-) More recently a panel of international experts reached consensus on the criteria for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), which is expected to unify the terminology, enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.^{9,10} This newer terminology and the more precise definition never occurred in this MS, I would suggest to discuss the evolution of NAFLD to MAFLD and the potential advantages that the use of MAFLD might provide for future studies. References: 1. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388-402. 2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328-57. 3. Firneisz G, Lakatos PL, Szalay F, Hungarian Viral Hepatitis Study G. Serum dipeptidyl peptidase IV (CD26; E.C.3.4.14.5.) activity in chronic hepatitis C. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 2001; 36(8): 877-80. 4. Andrieu T, Thibault V, Malet I, et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol 2003; 27(1): 59-68. 5. Harada T, Kim DW, Sagawa K, et al. Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. J Gen Virol



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

1995; 76 (Pt 5): 1215-21. 6. Hassan MM, Kaseb A, Etzel CJ, et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog 2013; 52 Suppl 1: E139-47. 7. Alam S, Ghosh J, Mustafa G, Kamal M, Ahmad N. Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. Hepat Med 2018; 10: 23-31. 8. Kosi-Trebotic L, Thomas A, Harreiter J, Chmelik M, Trattnig S, Kautzky-Willer A. Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients. Eur J Clin Invest 2017; 47(11): 829-38. 9. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73(1): 202-9. 10. Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int 2020; 40(6): 1254-61.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Hepatology

Manuscript NO: 58114

Title: Clinical Implications, Diagnosis, and Management of Diabetes in Patients with Chronic Liver Diseases

Reviewer's code: 02539650

Position: Peer Reviewer

Academic degree: DPhil

Professional title: Assistant Professor, Doctor

Reviewer's Country/Territory: Hungary

Author's Country/Territory: United States

Manuscript submission date: 2020-07-08

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2020-08-04 20:57

Reviewer performed review: 2020-08-07 13:36

Review time: 2 Days and 16 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

In this revised form the MS is now acceptable for publication.